Methylmercaptoimidazole en es it fr

Methylmercaptoimidazole Brand names, Methylmercaptoimidazole Analogs

Methylmercaptoimidazole Brand Names Mixture

  • No information avaliable

Methylmercaptoimidazole Chemical_Formula


Methylmercaptoimidazole RX_link

Methylmercaptoimidazole fda sheet

Methylmercaptoimidazole msds (material safety sheet)

Methylmercaptoimidazole MSDS

Methylmercaptoimidazole Synthesis Reference

No information avaliable

Methylmercaptoimidazole Molecular Weight

114.17 g/mol

Methylmercaptoimidazole Melting Point

146 oC

Methylmercaptoimidazole H2O Solubility

275 g/L

Methylmercaptoimidazole State


Methylmercaptoimidazole LogP


Methylmercaptoimidazole Dosage Forms

Tablet (5 or 10 mg)

Methylmercaptoimidazole Indication

For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.

Methylmercaptoimidazole Pharmacology

Used in the treatment of hyperthyroidism or an overactive thyroid gland, methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. It may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.

Methylmercaptoimidazole Absorption

Rapid with an oral bioavailability of 93%.

Methylmercaptoimidazole side effects and Toxicity

Oral LD50 in rats is 2250 mg/kg. Symptoms of overdose include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancy-topenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.

Methylmercaptoimidazole Patient Information

Patients should be instructed to report to their physicians any symptoms of agranulocytosis, such as fever or sore throat.

Methylmercaptoimidazole Organisms Affected

Humans and other mammals